Pharmacy

Top Medical News
Jairia Dela Cruz, 4 hours ago
In men with breast cancer, treatment with tamoxifen prolongs disease-free survival (DFS), cutting the risk of recurrence or death by more than 60 percent, as shown in a study.
Pearl Toh, 17 hours ago
The next-generation automated insulin delivery (AID) system significantly improved daytime glycaemic control without increasing hypoglycaemia over the current 670G hybrid closed-loop system on the market in young patients with type 1 diabetes (T1D), according to the FLAIR* trial presented during the ADA 2020 Annual Meeting.
Roshini Claire Anthony, 22 hours ago

Pembrolizumab may extend progression-free survival (PFS) in patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) who are ineligible for or have relapsed following autologous stem-cell transplant (auto-SCT), according to the phase III KEYNOTE-204 trial.

Audrey Abella, Yesterday
The type I interferon receptor antibody anifrolumab reduced disease activity and flares in patients with moderate-to-severe active systemic lupus erythematosus (SLE), results of the TULIP-1 and TULIP-2 trials have shown.
Jairia Dela Cruz, Yesterday
Regular users of proton pump inhibitors (PPIs) risk developing rheumatoid arthritis, and the risk increases proportionally with the duration of use, according to a study.
Elaine Soliven, Yesterday
 Treatment with tanezumab, a monoclonal antibody against nerve growth factor, significantly reduces pain intensity and improves daily function in patients with chronic low back pain, according to a trial presented at EULAR 2020.
Yesterday
New drug applications approved by US FDA as of 01 - 15 July 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Special Reports
Elvira Manzano, 28 Jun 2020
Hyperkalaemia (HK) occurrence and recurrence are frequent in advanced CKD*, creating a perfect storm for cardiovascular events and death, says Professor Juan-Jesus Carrero from the Karolinska Institute, Solna, Sweden, at ERA-EDTA 2020. Given these risks, acutely elevated potassium (K+) should merit clinical attention.
Roshini Claire Anthony, 28 Jun 2020

Roxadustat treatment for anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD) does not come with an increased risk of ophthalmic abnormalities, according to a phase III trial conducted in Japan.

Roshini Claire Anthony, 27 Jun 2020

Roxadustat may be a suitable treatment for anaemia in patients with non-dialysis dependent (NDD) chronic kidney disease (CKD), the phase III Dolomites* study showed.

26 Jun 2020
Dapagliflozin 5 mg and 10 mg FC tab
26 Jun 2020
Apalutamide 60 mg film-coated tab
26 Jun 2020
Rosuvastatin calcium 5 mg, 10 mg and 20 mg FC tab
Roshini Claire Anthony, 23 Apr 2020

Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.

Conference Reports
Pearl Toh, 15 Jul 2020
The next-generation automated insulin delivery (AID) system significantly improved daytime glycaemic control without increasing hypoglycaemia over the current 670G hybrid closed-loop system on the market in young patients with type 1 diabetes (T1D), according to the FLAIR* trial presented during the ADA 2020 Annual Meeting.
Roshini Claire Anthony, 15 Jul 2020

Pembrolizumab may extend progression-free survival (PFS) in patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) who are ineligible for or have relapsed following autologous stem-cell transplant (auto-SCT), according to the phase III KEYNOTE-204 trial.

Audrey Abella, 15 Jul 2020
The type I interferon receptor antibody anifrolumab reduced disease activity and flares in patients with moderate-to-severe active systemic lupus erythematosus (SLE), results of the TULIP-1 and TULIP-2 trials have shown.
Elaine Soliven, 15 Jul 2020
 Treatment with tanezumab, a monoclonal antibody against nerve growth factor, significantly reduces pain intensity and improves daily function in patients with chronic low back pain, according to a trial presented at EULAR 2020.
Audrey Abella, 14 Jul 2020
The monoclonal antibody galcanezumab may deliver benefit for treatment-resistant* episodic or chronic migraine, according to post hoc results of the CONQUER trial presented at AHS 2020.
Elaine Soliven, 14 Jul 2020
Treatment with DFN-15 may effectively alleviate pain and the most bothersome symptoms in adults with episodic migraine, according to two phase III studies presented at AHS 2020.
Roshini Claire Anthony, 13 Jul 2020

The addition of enzalutamide to androgen deprivation therapy (ADT) improved overall survival (OS) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC), demonstrated the phase III PROSPER* trial.

Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download